Clinical trial NCT05971056: Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
Official title: A Natural Experiment of Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Multiple Myeloma
Keywords: access to care
travel burden
financial toxicity
patient satisfaction
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2023-08-02
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: There is very limited data on the utilization of National Cancer Institute Comprehensive Cancer Center (NCI-CCC) satellite sites in general. Of what is available, most is in regards to providing chemotherapy at facilities closer to patients' home. These "satellite chemotherapy infusion centers", typically community-based treatment locations at community hospitals/facilities, freestanding clinics, or mobile units, are reported to be well liked by patients who utilize their services and reduce their travel times and expenses. In these studies patients still remained in the care of their current provider and site and are required to travel to the site for clinical visits and other appointments. It is currently unknown if patients are willing to transfer their care to a different provider to alleviate travel burden. In addition, although increased travel burden has been lower quality of life in cross-sectional studies, no data exists suggesting that these reducing travel burden can improve these outcomes intra-patient, to the knowledge of the investigators.

The patient roles of the multiple myeloma clinical providers at the Siteman primary location have grown in recent years. The providers have determined a need to refer some patients to the satellite sites to relieve congestion at the site while also hopefully improving the clinical experience for those patients. This study is a natural experiment of this process.


Eligibility criteria: Eligibility Criteria

* At least 18 years old
* Diagnosed with multiple myeloma
* Receiving care from a provider within the Division of Oncology at the primary Siteman Cancer Center site
* Resides within the catchment area of a Siteman Cancer Center satellite site
* Able to read, speak, and understand English
* Willing to provide informed consent

Primary outcomes:
measure: Proportion of eligible participants who successfully transfer to the provider at a satellite location
timeFrame: At time of transfer decision (day 1)
Secondary outcomes:
measure: Types of candidacy that providers use for transfer of care to satellite sites
timeFrame: At time of transfer decision (day 1)
measure: Treatment burden of participants as measured by the Modified Treatment Burden Questionnaire
timeFrame: Through completion of follow-up (estimated to be 6 months)
measure: Satisfaction of with participant-provider interactions as measured by the Questionnaire on the Quality of Physician-Patient Interaction
timeFrame: Through completion of follow-up (estimated to be 6 months)
measure: Financial toxicity of participants as measured by the Comprehensive Score for Financial Toxicity
timeFrame: Through completion of follow-up (estimated to be 6 months)
measure: Participant rationales for opting to transfer to a satellite site or maintain care at their usual site.
timeFrame: Through completion of follow-up (estimated to be 6 months)
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Mark Fiala, Ph.D., MSW
role: PRINCIPAL_INVESTIGATOR
References: